In examining recent analyst actions, we gain insights into how financial experts perceive Humana. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings ...

The firm has an Outperform rating on Humana. The Fly notes that back in October, Humana sued U.S. health agencies seeking to reverse a cut to crucial Medicare quality ratings, which translates to ...

According to Humana, CMS miscalculated its scores, which spelled bad news for the company's finances because higher star ...

Morgan Stanley raised the firm’s price target on Humana (HUM) to $290 from $285 and keeps an Equal Weight rating on the shares. While policy ...

Humana's stock has shown resilience, boosted by a 5% increase in Medicare Advantage payments. Read my analysis of HUM stock.

The decision, which Humana disclosed in a Tuesday filing with the court overseeing its lawsuit against the HHS, will be ...

NYSE HUM opened at $280.63 on Monday. Humana has a 12 month low of $213.31 and a 12 month high of $406.46. The company’s 50-day moving average price is $266.00 and its 200-day moving average ...

Kepler Capital analyst Anton Lund maintained a Buy rating on Humana AB (47H – Research Report) on April 10 and set a price target of SEK50.00.

Click here for access. * An analyst from Morgan Stanley persists with their Equal-Weight rating on Humana, maintaining a target price of $285. * An analyst from JP Morgan persists with their ...

The Centers for Medicare and Medicaid Services announced higher-than-expected Medicare Advantage payment rate increases for ...